Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data

Fautrel, Bruno; Combe, Bernard; Rincheval, Nathalie; Dougados, Maxime

doi:10.1136/annrheumdis-2011-200259

Cited by 51 publications

(42 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, rheumatologists proposed to revise the 2010 ACR criteria [16]. Despite the high sensitivity, the 2010 ACR criteria still miss some RA patients, especially symmetrical seronegative arthritis and limited joint involvement [47].…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis

Zhang¹,

Chen

2014

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:The aim of this work was to assess the diagnostic value of anti-CCP-3 and anti-CCP-2 for the diagnosis of rheumatoid arthritis (RA) and determine whether anti-CCP-3 more accurately identifies patients with rheumatoid arthritis than anti-CCP-2. PubMed and CNKI databases were searched for studies published in English and Chinese that examined the use of anti-CCP-3 and anti-CCP-2 in the diagnosis of known or suspected rheumatoid arthritis from January 2006 to July 2013. Seventeen included studies of methodological quality were rated by using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tools A randomeffects method was used to summarize sensitivities, specificities, positive and negative likelihood ratio (LR+ and LR-, respectively), and diagnostic odds ratio from 17 studies. The pooled sensitivity, specificity, LR+, LR-and diagnostic odds ratio for anti-CCP-3 were 0.737 (95% CI, 0.717-0.757), 0.933 (95% CI, 0.924-0.942), 11.096 (95% CI, 0.274 (95% CI, and 42.908 (95% CI,, respectively. For anti-CCP-2, the values were 0.719 (95% CI, 0.699-0.739), 0.960 (95% CI, 0.953-0.966), 17.485 (95% CI, 0.294 (95% CI,), respectively. With high specificity and moderate sensitivity, anti-CCP-2 and anti-CCP-3 played an important role in confirming the diagnosis of RA. Anti-CCP-3 did not have better diagnostic performances than anti-CCP-2, but anti-CCP-2 had evident heterogeneity compared to anti-CCP-3, especially in American patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis

Zhang¹,

Chen

2014

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…[12] Seven studies accepted two or three gold standards while the others only had one gold standard. This was identified as MTX in five studies, [6,[8][9][10]15] DMARDs in seven, [7,[9][10][11][12]14,15] and the primary expert's diagnosis of RA in five others. [7,[9][10][11][12]14,15] The main characteristics of all of the included studies are provided in Table 1.…”

Section: Results Of the Searchmentioning

confidence: 99%

“…A study flow diagram showing these articles is shown in Figure 1. [16] Description of the studies These 10 studies included cohorts from the Netherlands, [6][7][8] the United States, [13] France, [10] UK, [9] New Zealand, [14] Spain, [15] South Korea, [11] and Japan. [6,12] The three studies [6][7][8] from the Netherlands used different cohort databases: the Rotterdam Early Arthritis Cohort" (REACH), the Stop Arthritis Very Early (SAVE) trial, and the Leiden early arthritis clinic (EAC) cohort).…”

Section: Results Of the Searchmentioning

confidence: 99%

See 1 more Smart Citation

The Diagnostic Performance of the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

et al. 2013

View full text Add to dashboard Cite

Patients and methods:Between January 2010 and November 2012, an electronic search was conducted using MEDLINE (via PubMed), EMBASE, and Cochrane CENTRAL to find studies related to the diagnostic performance of the 2010 ACR/EULAR classification criteria for RA in patients with inflammatory synovitis. Subgroup analyses were performed according to the adopted gold standards. The sensitivity and specificity of the 2010 criteria were extracted or calculated. Summary receiver operating characteristic (sROC) curves were drawn to evaluate the differences between the 2010 and 1987 criteria. Results:We found 10 studies which were eligible for inclusion. Based on the 2010 criteria, the pooled information showed a sensitivity of 0.804 (95% confidence interval [CI]; range 0.737 to 0.857) and a specificity of 0.556 (95% CI; range 0.417 to 0.687) in the methotrexate (MTX) group, a sensitivity of 0.706 (95% CI; range 0.585 to 0.803) and a specificity of 0.691 (95% CI; range 0.583 to 0.782) in the disease-modifying antirheumatic drug (DMARD) group, and a sensitivity of 0.901 (95% CI; range 0.856 to 0.933) and a specificity of 0.539 (95% CI; range 0.429 to 0.645) in the expert group. The sensitivity and specificity were pooled under the bivariate binomial mixed model in this review due to the heterogeneous nature of the data. Compared to the 1987 criteria, the 2010 criteria showed a higher sensitivity, lower specificity and similar accuracy rate with more accuracy rate in the MTX group, compared the DMARD and expert groups. Conclusion:The 2010 ACR/EULAR criteria for RA have a better discriminative and diagnostic ability, higher sensitivity, and lower specificity than the 1987 criteria; therefore, we believe that it cannot be substituted for the 1987 criteria.

show abstract

“…These criteria, including ACPA levels, identify more patients with Rheumatoid Arthritis than the previous 1987 criteria 16 .…”

Section: Anti Cycliccitrullinated Peptide (Anti-ccp)mentioning

confidence: 99%

Romatoid Artritte Hastalık Aktivitesi ile Anti-CCP İlişkisi

Merza¹,

Tofiq²,

Radhi³

et al. 2014

Cukurova Medical Journal

View full text Add to dashboard Cite

Purpose: To determine the value of Anti-CCP as predictor for disease activity in rheumatoid arthritis assessed by DAS-28, and to find the effect of smoking on disease activity in rheumatoid arthritis. Materials and Methods: One hundred patients with rheumatoid arthritis involved in this study, consisted of 88 female and 12 male who fulfilled the 2010 ACR-EULAR classification criteria for rheumatoid arthritis attending the rheumatology department in general hospital, or attended the center of rheumatology and rehabilitation in sulaimani city, for 6 months ( from October, 2012 to March, 2013). Thorough Demographic information of patients was recorded through history of age, sex, and history of smoking, disease duration, physical evaluation according to DAS-28. and serological test for RF and Anti-CCP. Results: There was highly significant association between DAS-28 and Anti-CCP value (p =0.0001). there was no significant correlation between DAS-28 and RF (p= 0.252),According to smoking there was highly significant association between smoking with Anti-CCP value and DAS-28 (p=0.003-0.0001) respectively while there was no significant association between smoking and RF(p=0.15). Conclusion: A highly significant correlation was found between Anti-CCP value and disease activity in rheumatoid arthritis, smoker patients had higher value of Anti-CCP compared to non-smoker patients. Smokers demonstrated a more active and severe disease activity compared to non-smokers.

show abstract

Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data

Abstract: 2010 ACR/EULAR criteria identified more patients with RA than did 1987 criteria. The 2010 criteria failed to identify RA patients with symmetrical seronegative arthritis and limited joint involvement.

Cited by 51 publications

References 20 publications

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis

The Diagnostic Performance of the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Romatoid Artritte Hastalık Aktivitesi ile Anti-CCP İlişkisi

Contact Info

Product

Resources

About